Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
- 1 February 1996
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 347 (8998) , 347-352
- https://doi.org/10.1016/s0140-6736(96)90535-8
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Sulfasalazine in early rheumatoid arthritis. A 48‐week double‐blind, prospective, placebo‐controlled studyArthritis & Rheumatism, 1993
- Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study.Annals of the Rheumatic Diseases, 1992
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Rheumatoid Arthritis: Can the Long-Term Outcome Be Altered?Mayo Clinic Proceedings, 1988
- A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritisClinical Rheumatology, 1986
- Sulphasalazine1 in the Long Term Management of Rheumatoid ArthritisDrugs, 1986
- Low-dose Methotrexate in Rheumatoid Arthritis: Effect and Tolerance: An Open Trial and a Double-blind Randomized StudyScandinavian Journal of Rheumatology, 1986
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985
- Measurement of disability in Dutch rheumatoid arthritis patientsClinical Rheumatology, 1984
- A multicentre1) controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosageInflammation Research, 1976